Clinical Trial

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Study acronym: BOCIS
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-21.
Trial Details
NCT Number NCT06900647
Lead Sponsor Sun Yat-sen University
Conditions Metastatic Breast Cancer, Recurrent Breast Cancer
Enrollment 20 participants
Start Date 2025-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-02